RE:RE:RE:Today was the first socalbob wrote: Pandora -- you still in CRMD ? Wild ride the past month, and the rest of this week up to approval could be volatile. Hopefully TLT can have a similar move later this year with some new patient data.
CRMD one of the few examples of reverse split working and Nasday uplisting seems to have been a boost. But, I'm concerned too many of the WSB types now in CRMD for the quick flip. Very likely it will have a sell the news event with any other announcement regarding BO/JV or other plan for commercialization.
No, sad to say I got out of it last summer in the $4.50 range and picked up CYDY in the $2.30 range - CTDY being in the covid therapeutic field. As usual for me the CRMD eventually took off and the CYDY is still struggling through trials. The trial results apparently were just unblinded (finally) and management is having meetings with FDA, HC, and MHRA to discuss results and the path forward. It seems the shorters have taken advantage of the days news and knocked it back down to $4.32.
The optimistic outlook is that the results will be very positive but there are always detractors.
If they are as good as expected it should run but no one seems to know how long it now takes for them to publish the news.